It should be noted that hCG and other gonadotropins, including FSH, are widely used to restore spermatogenesis and fertility in male patients with hypogonadotrophic hypogonadism and other reproductive dysfunctions, but the results of such treatment are often unsuccessful, and this largely depends on the severity and origin of the impaired spermatogenesis, as well as on the etiology and pathogenesis of the reproductive disorder [79,80,81,82,83,84]. The gene discussed is BRD2; the disease is hypogonadotropic hypogonadism.